Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PULSAR: Sotatercept in Pulmonary Arterial Hypertension
NCT03496207Phase 2Completed
- Start
- Jun 2018
- Primary completion
- Mar 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 8
01
Overview
A Phase 2 trial of sotatercept in pulmonary arterial hypertension (PAH). Started Jun 2018; status: completed.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03496207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03496207.